Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan OKs Coverage for Susmed Insomnia App, Shionogi ADHD Therapy App
Japan’s Central Social Insurance Medical Council (Chuikyo) on May 13 approved insurance coverage for digital therapeutics developed by Susmed for insomnia and by Shionogi for ADHD, with reimbursements set to begin on June 1. The reimbursement price for Susmed’s insomnia…
To read the full story
Related Article
- Shionogi Releases Japan’s First Therapy App for Pediatric ADHD
June 8, 2026
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
REGULATORY
- DPP Lawmaker Calls for Inflation Relief in 2027 Off-Year Drug Price Revision
August 19, 2026
- CEA Review Group Wraps Up Technical Debate, Urges More Company Access
August 19, 2026
- Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
- PMDA Urges Quality-Driven Biosimilar Development as CES Waivers Take Hold
August 18, 2026
- Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…